^
Association details:
| Biomarker: | BRAF mutation + TET2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | pevonedistat (MLN4924) (NEDD8 activating enzyme inhibitor) + Beleodaq (belinostat) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study.
Published date:
05/25/2023
Excerpt:
Best response was stable disease in four patients, and CR in one patient….The patient achieving CR was a 54 year old female with BRAF and TET2 mutation, primarily refractory to 7+3 and also unresponsive to second line azacitidine and venetoclax….The combination of pevonedistat plus belinostat is safe in adult R/R AML with a manageable, primarily hematologic profile, and modest but notable activity...
DOI:
10.1200/JCO.2023.41.16_suppl.e19015
Trial ID:
